Cargando…

Quality of ADR reporting evaluated for remdesivir trials of COVID-19

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644420/ http://dx.doi.org/10.1007/s40278-020-84767-2

Ejemplares similares

Reported ADRs with chloroquine or hydroxychloroquine
Publicado: (2021)

Sex differences in ADR reports for drugs used to treat COVID-19
Publicado: (2020)

High incidence of ADRs in COVID-19 patients in China
Publicado: (2020)

Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs
Publicado: (2022)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain
Publicado: (2022)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
Publicado: (2022)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System
por: Ivos, R., et al.
Publicado: (2021)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

MHRA COVID-19 website for reporting ADRs and incidents
Publicado: (2020)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Network Characteristic Analysis of ADR-related Proteins and Identification of ADR-ADR Associations
por: Chen, Xiujie, et al.
Publicado: (2013)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
por: Hegazy, Sahar Kmal, et al.
Publicado: (2023)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
por: Buxeda, Anna, et al.
Publicado: (2021)

REMDESIVIR-INDUCED EXTREME SINUS BRADYCARDIA IN COVID-19
por: Hamilton, Steven A., et al.
Publicado: (2022)

Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Remdesivir for the Treatment of Covid-19 — Final Report
por: Beigel, John H., et al.
Publicado: (2020)

In silico evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment
por: Pagliarin, Luis Gustavo, et al.
Publicado: (2023)

Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance
por: Aiswarya, Dhanapalan, et al.
Publicado: (2020)

Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection
por: Habeeb, Ehsan, et al.
Publicado: (2023)

Critical reappraisal of remdesivir investigational trials in COVID-19
por: Brouqui, P., et al.
Publicado: (2020)

Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis
por: Paludan-Müller, Asger Sand, et al.
Publicado: (2021)

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
por: Wang, Yeming, et al.
Publicado: (2020)

Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19
por: Finn, Arkadiy, et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Impact of pharmacist recruitment on ADR reporting: Malaysian experience
por: Hadi, Muhammad Abdul, et al.
Publicado: (2011)

REMDESIVIR USE AND TRANSIENT COMPLETE ATRIOVENTRICULAR BLOCK IN THE COVID19 POSITIVE PATIENT
por: Hossain, Afif, et al.
Publicado: (2023)

Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells
por: WANG, LEI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_an81a2p20261d03ira0n9cmspk